Jeffrey S Miller

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2557107/publications.pdf

Version: 2024-02-01

331 papers	25,712 citations	7251 80 h-index	9346 148 g-index
339 all docs	339 docs citations	339 times ranked	19242 citing authors

#	Article	IF	Citations
1	Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. Blood, 2022, 139, 1177-1183.	0.6	41
2	Regulatory T cells: A review of manufacturing and clinical utility. Transfusion, 2022, 62, 904-915.	0.8	2
3	Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation. Translational Oncology, 2022, 16, 101318.	1.7	12
4	High Proliferating Regulatory T Cells Post-Transplantation Are Associated with Poor Survival in Lymphoma Patients Treated with Autologous Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 184.e1-184.e8.	0.6	6
5	Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial. Nature Medicine, 2022, 28, 392-400.	15.2	52
6	Human cytomegalovirus alters immune cell profile with potential implications for patient survival in head and neck cancer. Carcinogenesis, 2022, , .	1.3	0
7	CMV Triplex Vaccine to Enhance Adaptive NK and T-cell Reconstitution After Autologous Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 343.e1-343.e4.	0.6	2
8	Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer. Stem Cell Research and Therapy, 2022, 13, 165.	2.4	11
9	Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion. JCI Insight, 2022, 7, .	2.3	17
10	Promoting T and NK cell attack: preserving tumor MICA/B by vaccines. Cell Research, 2022, 32, 961-962.	5.7	1
11	A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. Leukemia, 2021, 35, 1586-1596.	3.3	57
12	Exploring the NK cell platform for cancer immunotherapy. Nature Reviews Clinical Oncology, 2021, 18, 85-100.	12.5	605
13	Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation. Blood Advances, 2021, 5, 1069-1080.	2.5	20
14	First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings. Blood Advances, 2021, 5, 1425-1436.	2.5	39
15	Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion. Cytotherapy, 2021, 23, 704-714.	0.3	7
16	Early Adaptive Natural Killer Cell Expansion Is Associated with Decreased Relapse After Autologous Transplantation for Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 310.e1-310.e6.	0.6	12
17	Following Transplantation for Acute Myelogenous Leukemia, Donor KIR Cen B02 Better Protects against Relapse than KIR Cen B01. Journal of Immunology, 2021, 206, 3064-3072.	0.4	8
18	Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+ NK cells to target myeloid leukemia. Molecular Therapy, 2021, 29, 3410-3421.	3.7	16

#	Article	IF	Citations
19	Infusion reactions in natural killer cell immunotherapy: a retrospective review. Cytotherapy, 2021, 23, 627-634.	0.3	7
20	Activation of ADAM17 by IL-15 Limits Human NK Cell Proliferation. Frontiers in Immunology, 2021, 12, 711621.	2.2	14
21	Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy. Molecular Diagnosis and Therapy, 2021, 25, 577-592.	1.6	27
22	Cellular Immunotherapyâ€"Highlights from TCT 2021. Transplantation and Cellular Therapy, 2021, 27, 527-532.	0.6	2
23	A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer. Cancers, 2021, 13, 3994.	1.7	23
24	CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL. Cancer Immunology, Immunotherapy, 2021, 70, 3701-3708.	2.0	26
25	Putting On the Gas and Taking Off the Brakes: A Novel Combinatorial Strategy to Enhance Tumor-Infiltrating Lymphocytes. Cancer Immunology Research, 2021, 9, 1110.	1.6	0
26	Activation Status Dictates the Function of Unlicensed Natural Killer Cells. Blood Advances, 2021, 5, 4219-4232.	2.5	1
27	Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy. Cell Stem Cell, 2021, 28, 2062-2075.e5.	5.2	80
28	Quantitative serum PCR argues against longâ€term persistence of HHVâ€6 viremia after umbilical cord blood transplantation. Transplant Infectious Disease, 2021, 23, e13555.	0.7	0
29	Novel cell and immune engagers in optimizing tumor specific immunity post autologous transplant in multiple myeloma. Transplantation and Cellular Therapy, 2021, 28, 61-61.	0.6	1
30	A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy. Molecular Therapy, 2020, 28, 52-63.	3.7	120
31	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. , 2020, 8, e000810.		5
32	Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager. Cancer Immunology Research, 2020, 8, 1139-1149.	1.6	39
33	Therapeutic effect of TRC105 and decitabine combination in AML xenografts. Heliyon, 2020, 6, e05242.	1.4	2
34	Ascorbic Acid Promotes KIR Demethylation during Early NK Cell Differentiation. Journal of Immunology, 2020, 205, 1513-1523.	0.4	12
35	Unraveling exhaustion in adaptive and conventional NK cells. Journal of Leukocyte Biology, 2020, 108, 1361-1368.	1.5	30
36	NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. Cancers, 2020, 12, 2659.	1.7	54

#	Article	IF	Citations
37	iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and antiâ€“PD-1 therapy. Science Translational Medicine, 2020, 12, .	5.8	133
38	Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies. Blood Reviews, 2020, 44, 100678.	2.8	38
39	Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML. Bone Marrow Transplantation, 2020, 55, 1975-1984.	1.3	8
40	Pluripotent stem cellâ€“derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity. Blood, 2020, 135, 399-410.	0.6	166
41	KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. Blood Advances, 2020, 4, 740-754.	2.5	42
42	Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. Blood Advances, 2020, 4, 1350-1356.	2.5	19
43	Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function. JCI Insight, 2020, 5, .	2.3	35
44	Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease. Journal of Clinical Investigation, 2020, 130, 4652-4662.	3.9	27
45	GTB-3550 TriKEâ„¢ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts. Blood, 2020, 136, 7-8.	0.6	19
46	Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma. Blood, 2020, 136, 8-8.	0.6	22
47	Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer (NK) Cells in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma. Blood, 2020, 136, 6-6.	0.6	8
48	FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma. Blood, 2020, 136, 4-5.	0.6	19
49	Triple Gene-Modified iPSC-Derived NK Cells Combined with Daratumumab for Targeted Immunotherapy Against AML. Blood, 2020, 136, 57-58.	0.6	0
50	A Phase I Study of FT538, a First-of-Kind, Off-the-Shelf, Multiplexed Engineered, iPSC-Derived NK Cell Therapy As Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Daratumumab or Elotuzumab in Relapsed/Refractory Multiple Myeloma. Blood, 2020, 136, 3-3.	0.6	4
51	CAR19 iPSC-Derived NK Cells Utilize the Innate Functional Potential Mediated through NKG2A-Driven Education and Override the HLA-E Check Point to Effectively Target B Cell Lymphoma. Blood, 2020, 136, 34-35.	0.6	2
52	Engineered iPSC-Derived NK Cells Expressing Recombinant CD64 for Enhanced ADCC. Blood, 2020, 136, 10-11.	0.6	3
53	Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up. Biology of Blood and Marrow Transplantation, 2019, 25, 56-62.	2.0	9
54	Harnessing Natural Killer Cell Antitumor Immunity: From the Bench to Bedside. Cancer Immunology Research, 2019, 7, 1742-1747.	1.6	37

#	Article	IF	Citations
55	Human NK Cell Development: One Road or Many?. Frontiers in Immunology, 2019, 10, 2078.	2.2	108
56	Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD. Blood, 2019, 134, 1670-1682.	0.6	49
57	Assessing Canonical and Adaptive Natural Killer Cell Function in Suppression Assays In Vitro. Methods in Molecular Biology, 2019, 1913, 153-166.	0.4	5
58	Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells. Gynecologic Oncology, 2019, 153, 149-157.	0.6	79
59	Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab. , 2019, 7, 70.		19
60	First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Advances, 2019, 3, 1970-1980.	2.5	164
61	Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL. Blood Advances, 2019, 3, 897-907.	2.5	64
62	Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia. Blood Advances, 2019, 3, 2448-2452.	2.5	14
63	The association of CMV with NK-cell reconstitution depends on graft source: results from BMT CTN-0201 samples. Blood Advances, 2019, 3, 2465-2469.	2.5	14
64	Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control. Journal of Immunotherapy, 2019, 42, 65-72.	1.2	27
65	Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis. Biology of Blood and Marrow Transplantation, 2019, 25, 949-954.	2.0	8
66	Natural Killer Cells in Cancer Immunotherapy. Annual Review of Cancer Biology, 2019, 3, 77-103.	2.3	122
67	Monocyte Subpopulation Recovery as Predictors of Hematopoietic Cell Transplantation Outcomes. Biology of Blood and Marrow Transplantation, 2019, 25, 883-890.	2.0	14
68	Adaptive NK cell reconstitution is associated with better clinical outcomes. JCI Insight, 2019, 4, .	2.3	59
69	Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming. Journal of Clinical Investigation, 2019, 129, 3770-3785.	3.9	125
70	Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD). Blood, 2019, 134, 804-804.	0.6	3
71	NK Cells Lacking CD38 Are Resistant to Oxidative Stress-Induced Death. Blood, 2019, 134, 3215-3215.	0.6	4
72	PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets. Blood, 2019, 134, 621-621.	0.6	2

#	Article	IF	Citations
73	FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies. Blood, 2019, 134, 301-301.	0.6	47
74	FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab. Blood, 2019, 134, 133-133.	0.6	11
75	Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM). Blood, 2019, 134, 777-777.	0.6	3
76	iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo. Blood, 2019, 134, 1933-1933.	0.6	1
77	First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood, 2018, 131, 2515-2527.	0.6	307
78	Association between recipient TNF rs361525 and acute GVHD: results from analysis of BMT CTN-0201 samples. Bone Marrow Transplantation, 2018, 53, 1069-1071.	1.3	1
79	Early Reconstitution of NK and Î³Î´ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy. Biology of Blood and Marrow Transplantation, 2018, 24, 1152-1162.	2.0	56
80	Interleukin-15 Complex Treatment Protects Mice from Cerebral Malaria by Inducing Interleukin-10-Producing Natural Killer Cells. Immunity, 2018, 48, 760-772.e4.	6.6	62
81	ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncology, The, 2018, 19, 694-704.	5.1	310
82	Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion, 2018, 58, 1458-1467.	0.8	19
83	Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML. Clinical Cancer Research, 2018, 24, 1834-1844.	3.2	136
84	Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models. Cytokine, 2018, 107, 105-112.	1.4	31
85	Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. Blood, 2018, 131, 1053-1062.	0.6	111
86	A Phase 1 Trial of CNDO-109â€“Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 1581-1589.	2.0	50
87	A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors. Clinical Cancer Research, 2018, 24, 1525-1535.	3.2	153
88	Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunology, Immunotherapy, 2018, 67, 483-494.	2.0	74
89	ALT-803 Transiently Reduces Simian Immunodeficiency Virus Replication in the Absence of Antiretroviral Treatment. Journal of Virology, 2018, 92, .	1.5	52
90	Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight, 2018, 3, .	2.3	165

#	Article	IF	Citations
91	Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Advances, 2018, 2, 909-922.	2.5	76
92	161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS. Blood Advances, 2018, 2, 1459-1469.	2.5	85
93	Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. Blood Advances, 2018, 2, 1580-1584.	2.5	24
94	Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. Cancer Immunology Research, 2018, 6, 766-775.	1.6	75
95	ARID5B regulates metabolic programming in human adaptive NK cells. Journal of Experimental Medicine, 2018, 215, 2379-2395.	4.2	98
96	Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma. , 2018, 6, 58.		48
97	Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2018, 24, 5552-5561.	3.2	150
98	Natural Killer Cellâ€“Based Therapies. , 2018, , 1575-1582.		1
99	Current strategies exploiting NKâ€cell therapy to treat haematologic malignancies. International Journal of Immunogenetics, 2018, 45, 237-246.	0.8	21
100	Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice. Molecular Therapy, 2018, 26, 1423-1434.	3.7	37
101	Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. American Journal of Hematology, 2018, 93, 1014-1019.	2.0	3
102	Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. Biology of Blood and Marrow Transplantation, 2018, 24, 618-622.	2.0	13
103	First-in-Human Clinical Trial to Determine the Safety and Potency of Inducible T Regulatory Cells after Allogeneic Hematopoietic Cell Transplantation. Blood, 2018, 132, 2112-2112.	0.6	1
104	Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study. Blood, 2018, 132, 71-71.	0.6	2
105	Off-the-Shelf Natural Killer Cells with Multi-Functional Engineering Using a Novel Anti-CD19 Chimeric Antigen Receptor Combined with Stabilized CD16 and IL15 Expression to Enhance Directed Anti-Tumor Activity. Blood, 2018, 132, 4541-4541.	0.6	2
106	Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients. Oncotarget, 2018, 9, 34810-34820.	0.8	44
107	Cyclin-Dependent Kinases (CDK) Signaling Blockade Potentiates NK Cell Mediated Cytotoxicity Against Acute Myelogenous Leukemia. Blood, 2018, 132, 4538-4538.	0.6	0
108	Efficient Scale-up and Pre-Clinical Evaluation of NKG2C+ Adaptive NK Cell Expansion for Therapy Against High-Risk AML/MDS. Blood, 2018, 132, 195-195.	0.6	0

#	Article	IF	Citations
109	Allogeneic hematopoietic cell transplantation in morphologic leukemiaâ€free aplastic state. American Journal of Hematology, 2017, 92, E549-E552.	2.0	0
110	NK Cells and Î³Î´T Cells for Relapse Protection after Allogeneic Hematopoietic Cell Transplantation (HCT). Current Stem Cell Reports, 2017, 3, 301-311.	0.7	13
111	Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. Seminars in Immunology, 2017, 31, 64-75.	2.7	110
112	Combined OX40L and mTOR blockade controls effector T cell activation while preserving T _{reg} reconstitution after transplant. Science Translational Medicine, 2017, 9, .	5.8	59
113	Dendritic Cell Recovery Impacts Outcomes after Umbilical Cord Blood and Sibling Donor Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2017, 23, 1925-1931.	2.0	5
114	GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity. Cancer Research, 2017, 77, 5664-5675.	0.4	114
115	Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigenâ€“Matched Grafts. Biology of Blood and Marrow Transplantation, 2017, 23, 126-133.	2.0	10
116	Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes. Biology of Blood and Marrow Transplantation, 2017, 23, 153-160.	2.0	12
117	Optimization of cGMP purification and expansion of umbilical cord bloodâ€“derived T-regulatory cells in support of first-in-human clinical trials. Cytotherapy, 2017, 19, 250-262.	0.3	41
118	HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. Frontiers in Immunology, 2017, 8, 675.	2.2	18
119	Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review. Frontiers in Immunology, 2017, 8, 1825.	2.2	39
120	Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control. JCI Insight, 2017, 2, .	2.3	90
121	Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity. Cancer Research and Treatment, 2017, 49, 1140-1152.	1.3	68
122	Fewer circulating natural killer cells 28 days after double cord blood transplantation predicts inferior survival and IL-15 response. Blood Advances, 2016, 1, 208-218.	2.5	9
123	Systems analysis uncovers inflammatory Th/Tc17-driven modules during acute GVHD in monkey and human T cells. Blood, 2016, 128, 2568-2579.	0.6	46
124	Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1602-1607.	2.0	41
125	Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells. Methods in Molecular Biology, 2016, 1441, 333-346.	0.4	124
126	Umbilical cord bloodâ€“derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood, 2016, 127, 1044-1051.	0.6	333

#	Article	IF	Citations
127	NK cells pave the road for alloengraftment. Blood, 2016, 127, 1083-1084.	0.6	2
128	Adoptive immunotherapy. , 2016, , 479-487.		0
129	Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells. Cancer Research, 2016, 76, 5696-5706.	0.4	146
130	Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise?. Clinical Cancer Research, 2016, 22, 5161-5163.	3.2	13
131	Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. Lancet Haematology,the, 2016, 3, e87-e98.	2.2	67
132	IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function. Clinical Cancer Research, 2016, 22, 3440-3450.	3.2	291
133	Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 487-492.	2.0	44
134	Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. Molecular Therapy, 2016, 24, 570-581.	3.7	168
135	In Vitro Induction of Human Regulatory T-Cells (iTregs) Using Conditions of Low Tryptophan Plus Kynurenines. Blood, 2016, 128, 1229-1229.	0.6	1
136	Immune Reconstitution after Umbilical Cord Blood Versus Peripheral Blood Progenitor Cell Transplantation in Adults Following Myeloablative Conditioning. Blood, 2016, 128, 2246-2246.	0.6	4
137	A Novel HIV Envelope Bi-Specific Killer Engager Enhances Natural Killer Cell Mediated ADCC Responses Against HIV-Infected Cells. Blood, 2016, 128, 2517-2517.	0.6	9
138	CD16-IL15-CD33 Trispecific Killer Engager (TriKE) Overcomes Cancer-Induced Immune Suppression and Induces Natural Killer Cell-Mediated Control of MDS and AML Via Enhanced Killing Kinetics. Blood, 2016, 128, 4291-4291.	0.6	8
139	Role of Recipient CD8+ T Cell Exhaustion in the Rejection of Adoptively Transferred Haploidentical NK Cells. Blood, 2016, 128, 503-503.	0.6	2
140	Continuous IL-15 Signaling Leads to Functional Exhaustion of Human Natural Killer Cells through Metabolic Changes That Alters Their In Vivo Anti-Tumor Activity. Blood, 2016, 128, 551-551.	0.6	4
141	Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker. Oncotarget, 2016, 7, 73830-73844.	0.8	52
142	Immune Reconstitution (IR) after Allogeneic Hematopoietic Cell Transplantation (alloHCT): Comparing Results in Recipients of Unrelated Umbilical Cord Blood (UCB) to Those with an HLA-Matched Sibling Donor Peripheral Blood (MSD PB). Blood, 2016, 128, 4590-4590.	0.6	0
143	GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. Blood, 2015, 126, 1621-1628.	0.6	104
144	Human group3 innate lymphoid cells express DR3 and respond to TL1A with enhanced ILâ€22 production and ILâ€2â€dependent proliferation. European Journal of Immunology, 2015, 45, 2335-2342.	1.6	38

#	Article	IF	Citations
145	Natural Killer Cell Adoptive Transfer Therapy. Cancer Journal (Sudbury, Mass), 2015, 21, 486-491.	1.0	99
146	Adaptive Natural Killer Cell and Killer Cell Immunoglobulinâ€“Like Receptorâ€“Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1653-1662.	2.0	50
147	Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies. Clinical Cancer Research, 2015, 21, 1267-1272.	3.2	60
148	Cytomegalovirus Infection Drives Adaptive Epigenetic Diversification of NK Cells with Altered Signaling and Effector Function. Immunity, 2015, 42, 443-456.	6.6	650
149	Regulation of Adaptive NK Cells and CD8 T Cells by HLA-C Correlates with Allogeneic Hematopoietic Cell Transplantation and with Cytomegalovirus Reactivation. Journal of Immunology, 2015, 195, 4524-4536.	0.4	35
150	Diversification and Functional Specialization of Human NK Cell Subsets. Current Topics in Microbiology and Immunology, 2015, 395, 63-93.	0.7	56
151	The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer. Current Topics in Microbiology and Immunology, 2015, 395, 225-243.	0.7	28
152	Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention. Science Translational Medicine, 2015, 7, 315ra191.	5.8	64
153	Human natural killer cell microRNA: differential expression of MIR181A1B1 and MIR181A2B2 genes encoding identical mature microRNAs. Genes and Immunity, 2015, 16, 89-98.	2.2	14
154	Antigen Level Matching at HLA-C Improves Long-Term Outcomes after Double Umbilical Cord Blood Transplantation. Blood, 2015, 126, 2022-2022.	0.6	1
155	Loss of Programmed Death Ligand-1 Expression on Donor T Cells Lessens Acute Graft-Versus-Host Disease Lethality. Blood, 2015, 126, 147-147.	0.6	0
156	ADAM17 and CD56low CD16low NK cells. Haematologica, 2015, 100, e331.	1.7	0
157	NK Cells in Therapy of Cancer. Critical Reviews in Oncogenesis, 2014, 19, 133-141.	0.2	98
158	Donor Killer Cell Ig-like Receptor B Haplotypes, Recipient HLA-C1, and HLA-C Mismatch Enhance the Clinical Benefit of Unrelated Transplantation for Acute Myelogenous Leukemia. Journal of Immunology, 2014, 192, 4592-4600.	0.4	139
159	Notch Signaling at Later Stages of NK Cell Development Enhances KIR Expression and Functional Maturation. Journal of Immunology, 2014, 193, 3344-3354.	0.4	51
160	Randomized Phase II Study of IL-2 With or Without an Allogeneic Large Multivalent Immunogen Vaccine for the Treatment of Stage IV Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 261-265.	0.6	8
161	The biology of <scp>NK</scp> cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (<scp>HCT</scp>). Immunological Reviews, 2014, 258, 45-63.	2.8	83
162	Transcriptional regulation of Munc13-4 expression in cytotoxic lymphocytes is disrupted by an intronic mutation associated with a primary immunodeficiency. Journal of Experimental Medicine, 2014, 211, 1079-1091.	4.2	35

#	Article	IF	Citations
163	Clinical utility of natural killer cells in cancer therapy and transplantation. Seminars in Immunology, 2014, 26, 161-172.	2.7	154
164	CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood, 2014, 123, 3016-3026.	0.6	220
165	Functional NK Cell Repertoires Are Maintained through IL-2RÎ± and Fas Ligand. Journal of Immunology, 2014, 192, 3889-3897.	0.4	20
166	A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. American Journal of Hematology, 2014, 89, 889-895.	2.0	82
167	Prevention of Graft-versus-Host Disease by Adoptive T Regulatory Therapy Is Associated with Active Repression of Peripheral Blood Toll-Like Receptor 5 mRNA Expression. Biology of Blood and Marrow Transplantation, 2014, 20, 173-182.	2.0	28
168	Expansion and Homing of Adoptively Transferred Human Natural Killer Cells in Immunodeficient Mice Varies with Product Preparation and InÂVivo Cytokine Administration: Implications for Clinical Therapy. Biology of Blood and Marrow Transplantation, 2014, 20, 1252-1257.	2.0	71
169	Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood, 2014, 123, 3855-3863.	0.6	357
170	KIR B or not to be?...that is the question for ALL. Blood, 2014, 124, 2623-2624.	0.6	4
171	Successful â€œin-flightâ€•activation of natural killer cells during long-distance shipping. Transfusion, 2013, 53, 398-403.	0.8	18
172	Natural killer cells: a review of manufacturing and clinical utility. Transfusion, 2013, 53, 404-410.	0.8	75
173	Isolation and characterization of canine natural killer cells. Veterinary Immunology and Immunopathology, 2013, 155, 211-217.	0.5	36
174	Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model. Cytotherapy, 2013, 15, 1297-1306.	0.3	54
175	Heterodimeric Bispecific Single-Chain Variable-Fragment Antibodies Against EpCAM and CD16 Induce Effective Antibody-Dependent Cellular Cytotoxicity Against Human Carcinoma Cells. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 274-282.	0.7	81
176	Adoptive Transfer of Umbilical Cord Blood-Derived Regulatory T Cells and Early Viral Reactivation. Biology of Blood and Marrow Transplantation, 2013, 19, 1271-1273.	2.0	93
177	Lineage relationships of human interleukin-22â€“producing CD56+ RORÎ³t+ innate lymphoid cells and conventional natural killer cells. Blood, 2013, 121, 2234-2243.	0.6	51
178	A Randomized Trial of One versus Two Doses of Influenza Vaccine after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 109-116.	2.0	57
179	Natural killer cells in graft-versus-host disease and graft-versus-leukemia. , 2013, , 327-356.		0
180	Targeting Natural Killer Cells to Acute Myeloid LeukemiaIn Vitrowith a CD16 Ã— 33 Bispecific Killer Cell Engager and ADAM17 Inhibition. Clinical Cancer Research, 2013, 19, 3844-3855.	3.2	208

#	Article	IF	Citations
181	Therapeutic applications: natural killer cells in the clinic. Hematology American Society of Hematology Education Program, 2013, 2013, 247-253.	0.9	77
182	Epigenetic regulation of NK cell differentiation and effector functions. Frontiers in Immunology, 2013, 4, 55.	2.2	71
183	Influence Of Killer Immunoglobulin-Like Receptor (KIR) and HLA Genotypes On Outcomes After Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation For Patients With AML and MDS: A Report From The Center For International Blood and Marrow Transplant Research Immunobiology Working Committee. Blood, 2013, 122, 159-159.	0.6	2
184	Death Receptor 3 (DR3) Is Expressed By Innate Lymphoid Cells (ILC) and Ligation By Tumor Like Antigen-1 (TL1A) Leads To Costimulation and Significant ILC Expansion. Blood, 2013, 122, 782-782.	0.6	2
185	Characterization Of a Weakly Expressed KIR2DL1 Allele. Blood, 2013, 122, 4847-4847.	0.6	0
186	Early NK Cell Proliferation After Umbilical Cord Blood Transplantation Is Associated With Superior Disease-Free Survival Due To Reduced Leukemia Relapse. Blood, 2013, 122, 4610-4610.	0.6	0
187	Control of Acute Myeloid Leukemia Relapse â€" Dance between KIRs and HLA. New England Journal of Medicine, 2012, 367, 866-868.	13.9	8
188	Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production. Molecular Cancer Therapeutics, 2012, 11, 2674-2684.	1.9	202
189	Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes. Blood, 2012, 119, 619-628.	0.6	79
190	Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood, 2012, 119, 2665-2674.	0.6	581
191	Human Cytomegalovirus (CMV)-Induced Memory-like NKG2C+ NK Cells Are Transplantable and Expand In Vivo in Response to Recipient CMV Antigen. Journal of Immunology, 2012, 189, 5082-5088.	0.4	331
192	Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood, 2012, 119, 3064-3072.	0.6	318
193	NK Cellsâ€"From Bench to Clinic. Biology of Blood and Marrow Transplantation, 2012, 18, S2-S7.	2.0	58
194	Natural Killer Cell Differentiation from Hematopoietic Stem Cells: A Comparative Analysis of Heparin- and Stromal Cellâ€"Supported Methods. Biology of Blood and Marrow Transplantation, 2012, 18, 536-545.	2.0	29
195	Successful Remission Rates and Survival after Lymphodepleting Chemotherapy and Donor Lymphocyte Infusion for Relapsed Hematologic Malignancies Postallogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 480-486.	2.0	43
196	Clinical Production and Therapeutic Applications of Alloreactive Natural Killer Cells. Methods in Molecular Biology, 2012, 882, 491-507.	0.4	11
197	Prolonged subcutaneous administration of 852A, a novel systemic tollâ€like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies. American Journal of Hematology, 2012, 87, 953-956.	2.0	50
198	Optimal Xenogeneic Adoptive Transfer of Human NK Cells: Fresh NK Cells and IL-15 Administration Are Superior to Frozen NK Cells and IL-2. Blood, 2012, 120, 346-346.	0.6	1

#	Article	IF	Citations
199	A Phase II Trial of Decitabine and Vorinostat in Combination with Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood, 2012, 120, 4307-4307.	0.6	3
200	Recombinant Human IL-15 Promotes in Vivo Expansion of Adoptively Transferred NK Cells in a First-in-Human Phase I Dose Escalation Study in Patients with AML. Blood, 2012, 120, 894-894.	0.6	9
201	Impact of Umbilical Cord Blood (UCB) T Regulatory Cells (Tregs) On Infection Risk Early After UCB Transplant. Blood, 2012, 120, 4188-4188.	0.6	0
202	Comparison of IPSS and IPSS-R Scoring in a Population Based Myelodysplastic Syndromes (MDS) Study. Blood, 2012, 120, 3841-3841.	0.6	1
203	A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy, 2011, 13, 98-107.	0.3	374
204	Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy, 2011, 3, 1445-1459.	1.0	134
205	Early Lymphocyte Recovery and Outcomes after Umbilical Cord Blood Transplantation (UCBT) for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2011, 17, 831-840.	2.0	56
206	National Cancer Instituteâ€™s First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Summary and Recommendations from the Organizing Committee. Biology of Blood and Marrow Transplantation, 2011, 17, 443-454.	2.0	39
207	Anti-HLA Antibodies in Double Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1704-1708.	2.0	70
208	Massive ex Vivo Expansion of Human Natural Regulatory T Cells (T _{regs}) with Minimal Loss of in Vivo Functional Activity. Science Translational Medicine, 2011, 3, 83ra41.	5.8	326
209	Natural killerâ€“cell differentiation by myeloid progenitors. Blood, 2011, 117, 3548-3558.	0.6	107
210	Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?. Blood, 2011, 118, 5084-5095.	0.6	163
211	NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. Blood, 2011, 118, 2784-2792.	0.6	117
212	Cutting Edge: MicroRNA-181 Promotes Human NK Cell Development by Regulating Notch Signaling. Journal of Immunology, 2011, 187, 6171-6175.	0.4	159
213	Myelodysplastic syndromes: the role of the immune system in pathogenesis. Leukemia and Lymphoma, 2011, 52, 2045-2049.	0.6	28
214	Killer Immunoglobulin-Like Receptor Transcriptional Regulation: A Fascinating Dance of Multiple Promoters. Journal of Innate Immunity, 2011, 3, 242-248.	1.8	30
215	Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood, 2011, 117, 1061-1070.	0.6	926
216	ADAM17, a Novel Metalloproteinase, Mediates CD16 and CD62L Shedding in Human NK Cells and Modulates IFNÎ³ Responses. Blood, 2011, 118, 2184-2184.	0.6	7

#	Article	IF	Citations
217	Haploidentical Natural Killer (NK) Cells Expanding In Vivo After Adoptive Transfer Exhibit Hyperfunction That Partially Overcomes Self Tolerance and Leads to Clearance of Refractory Leukemia. Blood, 2011, 118, 355-355.	0.6	5
218	Natural Killer (NK) Cells Respond to CMV Reactivation After Allogeneic Transplantation with An Increase in NKG2C+CD57+ Self-KIR+ NK Cells with Potent IFNÎ³ Production. Blood, 2011, 118, 356-356.	0.6	3
219	IL-2 Stimulated Treg Inhibit in Vitro Expansion of Haploidentical Natural Killer (NK) Cells, Which Is Partially Overcome with An IL-2-Diphtheria Toxin Fusion Protein In Vivo,. Blood, 2011, 118, 3611-3611.	0.6	0
220	The Impact of Bone Marrow Hematogones on Umbilical Cord Blood Transplant Outcomes in Acute Myeloid Leukemia Patients,. Blood, 2011, 118, 4148-4148.	0.6	0
221	Combination Therapy with Vorinostat and Bortezomib in Patients with High Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes. Blood, 2011, 118, 4277-4277.	0.6	0
222	Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood, 2010, 116, 2411-2419.	0.6	541
223	Allogeneic natural killer cells for refractory lymphoma. Cancer Immunology, Immunotherapy, 2010, 59, 1739-1744.	2.0	166
224	Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunology, Immunotherapy, 2010, 59, 1877-1884.	2.0	61
225	Different Patterns of Evolution in the Centromeric and Telomeric Regions of Group A and B Haplotypes of the Human Killer Cell Ig-Like Receptor Locus. PLoS ONE, 2010, 5, e15115.	1.1	235
226	Cutting Edge: KIR Antisense Transcripts Are Processed into a 28-Base PIWI-Like RNA in Human NK Cells. Journal of Immunology, 2010, 185, 2009-2012.	0.4	59
227	Clinical trials of NK cells for cancer. , 2010, , 555-570.		2
228	Impact of Cytomegalovirus (CMV) Reactivation after Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 215-222.	2.0	84
229	HLA-Haploidentical Stem Cell Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2010, 16, S57-S63.	2.0	37
230	Natural Killer Cell Killing of Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia Blasts by Killer Cell Immunoglobulin-Like Receptorâ€“Negative Natural Killer Cells after NKG2A and LIR-1 Blockade. Biology of Blood and Marrow Transplantation, 2010, 16, 612-621.	2.0	87
231	NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. Biology of Blood and Marrow Transplantation, 2010, 16, 565-586.	2.0	107
232	Decreased Infections in Recipients of Unrelated Donor Hematopoietic Cell Transplantation from Donors withÂan Activating KIR Genotype. Biology of Blood and Marrow Transplantation, 2010, 16, 1155-1161.	2.0	37
233	Introduction to the Reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 563-564.	2.0	22
234	In Vitro Development of Human Killerâ€“Immunoglobulin Receptor-Positive NK Cells. Methods in Molecular Biology, 2010, 612, 15-26.	0.4	38

#	Article	IF	Citations
235	Kinetics of Chimerism and Unit Predominance After Double Umbilical Cord Blood Transplantation. Blood, 2010, 116, 225-225.	0.6	6
236	Tim-3, a Novel Immune Receptor, Is Constitutively Expressed on Human Natural Killer Cells and Functions as An Activating Coreceptor. Blood, 2010, 116, 106-106.	0.6	0
237	Impact of Graft Source on Immune Recovery: Comparions Between Unrelated Umbilical Cord Blood (UCB), HLA Matched Sibling (Sib) Donor and Autologous (Auto) Hematopoietic Stem Cells.. Blood, 2010, 116, 3731-3731.	0.6	0
238	NK Education: Disassociation Between Recovery of Cytoxicity and Cytokine Production In NK Cells After Allogeneic Transplantation.. Blood, 2010, 116, 1462-1462.	0.6	0
239	HLA Class I Subtype-Dependent Expansion of KIR3DS1 ⁺ and KIR3DL1 ⁺ NK Cells during Acute Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2009, 83, 6798-6805.	1.5	170
240	Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: Analysis of Graft Sources and Long-Term Outcome. Journal of Clinical Oncology, 2009, 27, 3634-3641.	0.8	92
241	The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells. British Journal of Haematology, 2009, 147, 185-191.	1.2	85
242	Promising Progression-Free Survival for Patients Low and Intermediate Grade Lymphoid Malignancies after Nonmyeloablative Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 214-222.	2.0	36
243	Activated Notch Supports Development of Cytokine Producing NK Cells Which Are Hyporesponsive and Fail to Acquire NK Cell Effector Functions. Biology of Blood and Marrow Transplantation, 2009, 15, 183-194.	2.0	24
244	Minimally invasive versus open Roux-en-Y gastric bypass: effect on immune effector cells. Surgery for Obesity and Related Diseases, 2009, 5, 181-193.	1.0	12
245	Should natural killer cells be expanded in vivo or ex vivo to maximize their therapeutic potential?. Cytotherapy, 2009, 11, 259-260.	0.3	16
246	The transcription factor c-Myc enhances KIR gene transcription through direct binding to an upstream distal promoter element. Blood, 2009, 113, 3245-3253.	0.6	46
247	Limited role of MHC class I chainâ€"related gene A (MICA) typing in assessing graft-versus-host disease risk after fully human leukocyte antigenâ€"matched unrelated donor transplantation. Blood, 2009, 114, 4753-4754.	0.6	26
248	Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood, 2009, 113, 726-732.	0.6	408
249	Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood, 2009, 113, 5628-5634.	0.6	147
250	â€œSelfâ€•reflection by KIR. Blood, 2009, 114, 2-3.	0.6	9
251	Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood, 2009, 114, 4293-4299.	0.6	276
252	Cellular Adoptive Immunotherapy After Autologous and Allogeneic Hematopoietic Stem Cell Transplantation. Cancer Treatment and Research, 2009, 144, 497-537.	0.2	5

#	Article	IF	Citations
253	Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15. Experimental Hematology, 2008, 36, 598-608.	0.2	40
254	Use of natural killer cells as immunotherapy for leukaemia. Best Practice and Research in Clinical Haematology, 2008, 21, 467-483.	0.7	35
255	Thoracoscopic Versus Thoracotomy Approaches to Lobectomy: Differential Impairment of Cellular Immunity. Annals of Thoracic Surgery, 2008, 86, 1735-1744.	0.7	109
256	Human Polymorphism and Variable Outcomes of Cancer Chemotherapy and Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 120-128.	2.0	1
257	Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched Related Donor. Biology of Blood and Marrow Transplantation, 2008, 14, 282-289.	2.0	119
258	Similar and Promising Outcomes in Lymphoma Patients Treated with Myeloablative or Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 538-545.	2.0	56
259	Umbilical Cord Blood T Cells Express Multiple Natural Cytotoxicity Receptors after IL-15 Stimulation, but Only NKp30 Is Functional. Journal of Immunology, 2008, 181, 4507-4515.	0.4	37
260	Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood, 2008, 112, 2847-2857.	0.6	134
261	Response: The role of G-CSF on the risk of graft-versus-host disease after donor lymphocyte infusions. Blood, 2008, 111, 5256-5257.	0.6	0
262	How killers kill. Blood, 2008, 112, 213-213.	0.6	7
263	Autologous Large Multivalent Immunogen Vaccine in Patients With Metastatic Melanoma and Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 173-181.	0.6	30
264	Blocking Inhibitory KIR Is Insufficient for Optimal Killing of AML and ALL Targets: Additional Requirements for NKG2A and LIR-1 Blockade. Blood, 2008, 112, 2906-2906.	0.6	10
265	Successful Haploidentical Hematopoietic Cell Engraftment Using a Non-Myeloablative Preparative Regimen Including Natural Killer (NK) Cells. Blood, 2008, 112, 827-827.	0.6	15
266	First in Human Phase I Trial of 852A, a Novel Systemic Toll-like Receptor 7 Agonist, to Activate Innate Immune Responses in Patients with Advanced Cancer. Clinical Cancer Research, 2007, 13, 7119-7125.	3.2	144
267	A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood, 2007, 110, 578-586.	0.6	202
268	Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood, 2007, 109, 5058-5061.	0.6	270
269	Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood, 2007, 110, 3064-3070.	0.6	489
270	The unexpected effect of cyclosporin A on CD56+CD16â˜ and CD56+CD16+ natural killer cell subpopulations. Blood, 2007, 110, 1530-1539.	0.6	131

#	Article	IF	Citations
271	Adoptive Therapy with T Cells/NK Cells. Biology of Blood and Marrow Transplantation, 2007, 13, 33-42.	2.0	15
272	Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients of Unrelated Donor (URD) Umbilical Cord Blood (UCB). Biology of Blood and Marrow Transplantation, 2007, 13, 1145-1152.	2.0	59
273	iTRAQ Is a Useful Method To Screen for Membrane-Bound Proteins Differentially Expressed in Human Natural Killer Cell Types. Journal of Proteome Research, 2007, 6, 644-653.	1.8	67
274	Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood, 2007, 110, 2761-2763.	0.6	82
275	Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: A comparative clinical analysis. American Journal of Hematology, 2007, 82, 867-872.	2.0	60
276	Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion, 2007, 47, 520-528.	0.8	104
277	A novel method for KIR-ligand typing by pyrosequencing to predict NK cell alloreactivity. Clinical Immunology, 2007, 123, 272-280.	1.4	13
278	Dyskeratosis Congenita: Low Regimen-Related Toxicity Following Hematopoietic Cell Transplantation (HCT) Using a Reduced Intensity Conditioning Regimen.. Blood, 2007, 110, 2005-2005.	0.6	7
279	Stromal Cells Support a Myeloid Pathway of Human NK Cell Differentiation.. Blood, 2007, 110, 1336-1336.	0.6	0
280	Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. International Immunology, 2006, 18, 1115-1126.	1.8	146
281	Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood, 2006, 108, 3824-3833.	0.6	138
282	The Effect of KIR Ligand Incompatibility on the Outcome of Unrelated Donor Transplantation: A Report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. Biology of Blood and Marrow Transplantation, 2006, 12, 876-884.	2.0	241
283	Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkinâ€™s Lymphoma. Biology of Blood and Marrow Transplantation, 2006, 12, 1065-1072.	2.0	171
284	Suppressor Function of Umbilical Cord Blood-Derived CD4+CD25+ T-Regulatory Cells Exposed to Graft-versus-Host Disease Drugs. Transplantation, 2006, 82, 23-29.	0.5	20
285	Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood, 2005, 105, 1343-1347.	0.6	824
286	KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood, 2005, 106, 4370-4376.	0.6	208
287	The Minnesota Molecular and Cellular Therapeutics Facility: A State-of-the-Art Biotherapeutics Engineering Laboratory. Transfusion Medicine Reviews, 2005, 19, 217-228.	0.9	17
288	Epigenetic Control of Highly Homologous Killer Ig-Like Receptor Gene Alleles. Journal of Immunology, 2005, 175, 5966-5974.	0.4	66

#	Article	IF	Citations
289	Human Embryonic Stem Cell-Derived NK Cells Acquire Functional Receptors and Cytolytic Activity. Journal of Immunology, 2005, 175, 5095-5103.	0.4	198
290	FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function. Biology of Blood and Marrow Transplantation, 2005, 11, 23-34.	2.0	38
291	Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma. Biology of Blood and Marrow Transplantation, 2005, 11, 129-135.	2.0	25
292	Diminished neo-antigen response to keyhole limpet hemocyanin (KLH) vaccines in patients after treatment with chemotherapy or hematopoietic cell transplantation. Clinical Immunology, 2005, 117, 144-151.	1.4	25
293	Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood, 2005, 105, 3051-3057.	0.6	1,574
294	Chronic Graft Versus Host Disease (cGVHD) Following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate in Recipients of Unrelated Donor (URD) Umbilical Cord Blood (UCB).. Blood, 2005, 106, 1814-1814.	0.6	2
295	Human Embryonic Stem Cells Differentiate into Functional Natural Killer Cells with the Capacity To Mediate Anti-Tumor Activity.. Blood, 2005, 106, 763-763.	0.6	0
296	C-MYC Induces KIR Expression Via a Novel Control Region Upstream of the Conventional Adult KIR Promoter.. Blood, 2005, 106, 764-764.	0.6	0
297	Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation, 2004, 10, 171-177.	2.0	13
298	Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biology of Blood and Marrow Transplantation, 2004, 10, 395-404.	2.0	48
299	Successful Remission of Poor Prognosis AML after Adoptive Transfer and In Vivo Expansion of Human Haploidentical NK Cells.. Blood, 2004, 104, 260-260.	0.6	2
300	Acute Graft-Versus-Host Disease: Clinical Presentation and Response to Therapy Following Umbilical Cord Blood Transplant.. Blood, 2004, 104, 2148-2148.	0.6	0
301	Fludarabine Is Superior to Cladribine When Added to Busulfan and Low Dose TBI as Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT): A Prospective Randomized Trial.. Blood, 2004, 104, 1825-1825.	0.6	8
302	BCR/ABL alters the function of NK cells and the acquisition of killer immunoglobulin-like receptors (KIRs). Blood, 2003, 101, 3527-3533.	0.6	23
303	Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood, 2003, 102, 1915-1919.	0.6	397
304	Biology of Natural Killer Cells in Cancer and Infection. Cancer Investigation, 2002, 20, 405-419.	0.6	60
305	Clinical-Scale Selection of Anti-CD3/CD28â€“Activated T Cells After Transduction with a Retroviral Vector Expressing Herpes Simplex Virus Thymidine Kinase and Truncated Nerve Growth Factor Receptor. Human Gene Therapy, 2002, 13, 979-988.	1.4	35
306	The BCR/ABL Transgene Causes Abnormal NK Cell Differentiation and Can Be Found in Circulating NK Cells of Advanced Phase Chronic Myelogenous Leukemia Patients. Journal of Immunology, 2002, 168, 643-650.	0.4	35

#	Article	IF	Citations
307	Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood, 2002, 100, 3825-3827.	0.6	356
308	Determinants of survival after human leucocyte antigen-matched unrelated donor bone marrow transplantation in adults. British Journal of Haematology, 2002, 118, 101-107.	1.2	17
309	The Biology of Natural Killer Cells and Implications for Therapy of Human Disease. Journal of Hematotherapy and Stem Cell Research, 2001, 10, 451-463.	1.8	34
310	Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. American Journal of Medicine, 2001, 110, 339-346.	0.6	65
311	Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. Blood, 2001, 98, 705-713.	0.6	212
312	T-cell factor-1 expression during human natural killer cell development and in circulating CD56+ bright natural killer cells. Experimental Hematology, 2001, 29, 499-506.	0.2	11
313	The biology of natural killer cells in cancer, infection, and pregnancy. Experimental Hematology, 2001, 29, 1157-1168.	0.2	117
314	Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer. Experimental Hematology, 2000, 28, 352.	0.2	5
315	Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer. Experimental Hematology, 2000, 28, 96-103.	0.2	35
316	Single Adult Human CD34+/Linâ¯/CD38â¯ Progenitors Give Rise to Natural Killer Cells, B-Lineage Cells, Dendritic Cells, and Myeloid Cells. Blood, 1999, 93, 96-106.	0.6	172
317	Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Experimental Hematology, 1999, 27, 1533-1541.	0.2	183
318	Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis. Experimental Hematology, 1999, 27, 1519-1527.	0.2	26
319	Single Adult Human CD34+/Linâ¯/CD38â¯ Progenitors Give Rise to Natural Killer Cells, B-Lineage Cells, Dendritic Cells, and Myeloid Cells. Blood, 1999, 93, 96-106.	0.6	52
320	INNOVATIVE THERAPY FOR CHRONIC MYELOGENOUS LEUKEMIA. Hematology/Oncology Clinics of North America, 1998, 12, 173-206.	0.9	8
321	Ex Vivo Culture of CD34+/Linâ¯/DRâ¯ Cells in Stroma-Derived Soluble Factors, Interleukin-3, and Macrophage Inflammatory Protein-1Î± Maintains Not Only Myeloid But Also Lymphoid Progenitors in a Novel Switch Culture Assay. Blood, 1998, 91, 4516-4522.	0.6	47
322	FLT-3 Ligand and Marrow Stroma-Derived Factors Promote CD3Î³, CD3Î´, CD3Î¶, and RAG-2 Gene Expression in Primary Human CD34+LINâ¯DRâ¯ Marrow Progenitors. Blood, 1998, 91, 1662-1670.	0.6	17
323	FLT-3 Ligand and Marrow Stroma-Derived Factors Promote CD3Î³, CD3Î´, CD3Î¶, and RAG-2 Gene Expression in Primary Human CD34+LINâ¯DRâ¯ Marrow Progenitors. Blood, 1998, 91, 1662-1670.	0.6	1
324	Ex Vivo Culture of CD34+/Linâ¯/DRâ¯ Cells in Stroma-Derived Soluble Factors, Interleukin-3, and Macrophage Inflammatory Protein-1Î± Maintains Not Only Myeloid But Also Lymphoid Progenitors in a Novel Switch Culture Assay. Blood, 1998, 91, 4516-4522.	0.6	3

#	Article	IF	Citations
325	The Role of Autologous Natural Killer Cells in Chronic Myelogenous Leukemia. Leukemia and Lymphoma, 1997, 27, 387-399.	0.6	21
326	Natural Killer (NK) Cells Are Functionally Abnormal and NK Cell Progenitors Are Diminished in Granulocyte Colony-Stimulating Factorâ€"Mobilized Peripheral Blood Progenitor Cell Collections. Blood, 1997, 90, 3098-3105.	0.6	91
327	Production of Human Natural Killer Cells for Adoptive Immunotherapy Using a Computer-Controlled Stirred-Tank Bioreactor. Stem Cells and Development, 1996, 5, 475-483.	1.0	36
328	Natural Killer Cell Proliferation Is Dependent on Human Serum and Markedly Increased Utilizing an Enriched Supplemented Basal Medium. Stem Cells and Development, 1995, 4, 149-158.	1.0	35
329	Population dynamics of human activated natural killer cells in culture. Biotechnology and Bioengineering, 1994, 43, 685-692.	1.7	13
330	Therapy for chronic myelogenous leukemia with marrow transplantation. Current Opinion in Oncology, 1993, 5, 262-269.	1.1	12
331	Natural Killer Cells and Allogeneic Hematopoietic Cell Transplantation. , 0, , 163-175.		0